Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies.

ABSTRACT:

Objective

To examine the population-level impacts of the introduction of novel cancer therapies with high cost in the United States, using immunotherapies in advanced nonsmall cell lung cancer (NSCLC) as an example.

Data sources

Surveillance, Epidemiology, and End Results data in 2012-2015 linked to Medicare fee-for-service claims until 2016.

Study design

We examined population-level trends in treatment patterns, survival, and Medicare spending in patients diagnosed with advanced NSCLC, the leading cause of cancer death in the United States, between 2012 and 2015. We estimated the percentage of patients who received any antineoplastic therapy within two years of diagnosis, including novel immunotherapies. We compared the trends in overall survival and mean two-year Me

SUBMITTER: Youn B 

PROVIDER: S-EPMC8143675 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature